tetano
Editor, Senior Moderator
Am Heart J Plus
. 2025 Dec 2:61:100690.
doi: 10.1016/j.ahjo.2025.100690. eCollection 2026 Jan. Cardiac troponin T elevation predicts mortality in hospitalized COVID-19 patients
Katelyn A Bruno[SUP] 1 2 [/SUP], R Scott Wright[SUP] 3 [/SUP], Joshua Culberson[SUP] 1 2 [/SUP], Mikolaj A Wieczorek[SUP] 4 [/SUP], David O Hodge[SUP] 4 [/SUP], Patrick W Johnson[SUP] 4 [/SUP], Yomary A Jimenez[SUP] 2 [/SUP], Emily R Whelan[SUP] 1 [/SUP], Jose M Malavet[SUP] 1 [/SUP], Kathryn F Larson[SUP] 3 [/SUP], Jonathon W Senefeld[SUP] 5 6 [/SUP], Chad C Wiggins[SUP] 5 7 [/SUP], Stephen A Klassen[SUP] 8 [/SUP], Jacob Ricci[SUP] 2 [/SUP], Taimur Sher[SUP] 9 [/SUP], Rickey E Carter[SUP] 4 [/SUP], Michael J Joyner[SUP] 5 [/SUP], DeLisa Fairweather[SUP] 1 [/SUP], Allan S Jaffe[SUP] 3 10 [/SUP]
Affiliations
Objective: To evaluate if cardiac troponin values predict poor outcomes in COVID-19 patients across the range of patients of different sex and age.
Methods: We examined high-sensitivity cardiac troponin T (hs-cTnT) levels in 1050 severely ill hospitalized COVID-19 patients who had hs-cTnT data available and participated in the Expanded Access Program for convalescent plasma study during the first wave (April-August 2020) of the COVID-19 pandemic.
Results: We observed a continuous relationship between hs-cTnT levels and mortality in hospitalized males and females with COVID-19. This finding was present regardless of sex or age.
Conclusion: These data indicate the prognostic ability of hs-cTnT to predict mortality in hospitalized COVID-19 patients across all relevant patient groups.Clinical Trials registration number: NCT04338360.
Keywords: Convalescent plasma; Coronavirus disease 2019; High sensitivity troponin.
. 2025 Dec 2:61:100690.
doi: 10.1016/j.ahjo.2025.100690. eCollection 2026 Jan. Cardiac troponin T elevation predicts mortality in hospitalized COVID-19 patients
Katelyn A Bruno[SUP] 1 2 [/SUP], R Scott Wright[SUP] 3 [/SUP], Joshua Culberson[SUP] 1 2 [/SUP], Mikolaj A Wieczorek[SUP] 4 [/SUP], David O Hodge[SUP] 4 [/SUP], Patrick W Johnson[SUP] 4 [/SUP], Yomary A Jimenez[SUP] 2 [/SUP], Emily R Whelan[SUP] 1 [/SUP], Jose M Malavet[SUP] 1 [/SUP], Kathryn F Larson[SUP] 3 [/SUP], Jonathon W Senefeld[SUP] 5 6 [/SUP], Chad C Wiggins[SUP] 5 7 [/SUP], Stephen A Klassen[SUP] 8 [/SUP], Jacob Ricci[SUP] 2 [/SUP], Taimur Sher[SUP] 9 [/SUP], Rickey E Carter[SUP] 4 [/SUP], Michael J Joyner[SUP] 5 [/SUP], DeLisa Fairweather[SUP] 1 [/SUP], Allan S Jaffe[SUP] 3 10 [/SUP]
Affiliations
- PMID: 41446701
- PMCID: PMC12723113
- DOI: 10.1016/j.ahjo.2025.100690
Objective: To evaluate if cardiac troponin values predict poor outcomes in COVID-19 patients across the range of patients of different sex and age.
Methods: We examined high-sensitivity cardiac troponin T (hs-cTnT) levels in 1050 severely ill hospitalized COVID-19 patients who had hs-cTnT data available and participated in the Expanded Access Program for convalescent plasma study during the first wave (April-August 2020) of the COVID-19 pandemic.
Results: We observed a continuous relationship between hs-cTnT levels and mortality in hospitalized males and females with COVID-19. This finding was present regardless of sex or age.
Conclusion: These data indicate the prognostic ability of hs-cTnT to predict mortality in hospitalized COVID-19 patients across all relevant patient groups.Clinical Trials registration number: NCT04338360.
Keywords: Convalescent plasma; Coronavirus disease 2019; High sensitivity troponin.